LANCASTER, Pa., Feb. 19, 2018 /PRNewswire-PRWeb/ -- Eurofins Central Laboratory, a member of the leading international
The 10,000 square foot facility is strategically located in near proximity of the largest UPS worldwide air facility in the US, Worldhub® at the Louisville International Airport. The facility has a purpose built design of the work floor based on the Kit Assembly work flow and has an optimized lay-out of its warehousing.
As a continued commitment to providing BOLD central laboratory services, Eurofins Central Laboratory is a turnkey provider which deploys lean, globally standardized processes, enabling high quality GMP compliant kits to be distributed worldwide.
"Our care for patient specimens does not commence when clinical trial samples arrive at one of our Central Laboratory facilities in US, Europe, or Asia. We made the decision to further enhance transparency and control over the production and distribution of our, customized specimen collection kits," explains Elena Logan, Senior Vice President. "With 2 Eurofins wholly owned Kit Packing and Distribution Facilities in US and Europe, we are in full control to use our wealth of experience to deploy the best processes, people and systems to not only meet, but exceed our clients' expectations".
"This year, we assembled and distributed over 1 Million clinical trial specimen collection kits globally, as well as provided patient centric self-collection kits directly to patients' homes. Our Kit Packing and Distribution Services are also available as a stand-alone service. With an integrated MRP [Material Requirements Planning] system, the Louisville operation allows quick expansion of services into 2018 and beyond," said Lisa Fotheringham, Vice President, Operations.
Elena Logan, Senior Vice President Eurofins Central Laboratory elaborates: "With increasing complexity of clinical study protocols, and a focus on moving trials closer to patients, specimen collection kits have become more complex. Eurofins Central Laboratory is dedicated to challenging the status quo and continually evaluates ways to improve the client and site experience while remaining competitive in the marketplace. This investment in our Louisville facility is an example of such commitment"
About Eurofins Central Laboratory Eurofins is a pure-play leading global Central Laboratory with extensive experience in Phases I-IV clinical trials, and works with top Pharma, biotech, and CROs to support drug development through laboratory testing, validation and assay development. We have the informational infrastructure, project and investigator support, analytical capabilities and experience to develop and run assays in CAP/CLIA and GLP-like regulatory frameworks.
Eurofins Central Laboratory operates its four wholly-owned central laboratories in the US, Europe, Singapore and China under the same international quality standards, regulatory guidelines, SOPs and IT infrastructure globally. Eurofins Central Laboratory has a broad range of equivalent testing capabilities, experience, leadership and dedicated staff, as well as harmonized standards and regulatory framework of four global analytical sites, that strongly positions Eurofins to be a solid, dependable central lab partner for clinical development programs.
Reliable, high quality laboratory data is pivotal to the success of clinical trials. At Eurofins Central Laboratory, we are BOLD. We go beyond the expected. Since laboratory testing is our sole focus, there are no distractions allowing us to remain laser focused on the best science, technology and people so you get what you deserve. You will benefit from the fact that we are part of one of the world's leading laboratory organizations. This means you enjoy end-to-end testing solutions, free from the worry of coordinating multiple vendors. Our testing capabilities are unsurpassed and we are setting new standards with our GLP capabilities embedded within the Eurofins Central Laboratory.
Notes for the editor: Eurofins – a global leader in bio-analysis Eurofins Scientific through its subsidiaries (hereinafter sometimes "Eurofins" or "the Group") believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 30,000 staff in 375 laboratories across 41 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.
SOURCE Eurofins Central Laboratory
Subscribe to our Free Newsletters!
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...
Are you gluten intolerant? Stay away from gluten allergy and celiac disease by shifting to ...
Moxetumomab pasudotox-tdfk is used to treat hairy cell leukemia (a form of chronic lymphocytic ...View All